A Review of Four Approved Swine Flu Vaccines’ Ingredients

[Guest guest]

http://articles.mercola.com/sites/articles/archive/2009/11/05/Swine-Flu-Vaccine-\

Ingredients.aspx

 

I've said it before, but I'll say it again: I'm not anti-vaccines, but rather

pro vaccine-safety. That means, I strongly believe that we should only inject

substances into our bodies, and especially into the bodies of infants and the

unborn, that have been rigorously studied and proven safe both short-term and

long-term.

As it stands now, we've spent decades injecting materials into the bodies of

young and old alike, without sufficient amounts of safety testing of the

ingredients, and our society is showing the signs of this neglect.

 

Neurological dysfunction and disorders such as autism and Alzheimer's have been

growing steadily and show no signs of slowing down.

Mercury, in the form of thimerosal, is included in the majority of all flu

vaccines as a preservative in multi-dose vials. Thimerosal-free single-dose

vials are typically reserved for infants under the age of three, and pregnant

women only.

 

I recently published a long list of studies confirming the health dangers of

thimerosal -- proof that those who claim " thimerosal has never been shown to

cause any damage " are not telling you the truth. There's plenty of evidence to

the contrary, and if you missed that article, I recommend you review it now.

But thimerosal is not the only questionable and potentially dangerous ingredient

in flu vaccines.

Adjuvants Explained

In order for a vaccine to be considered effective, your immune response to the

vaccine should be to produce antibodies to the live or dead viruses in the

vaccine (the antigen). An adjuvant is a substance added to a vaccine to improve

your immune response to the antigen. The word comes from the Latin adjuvare,

which means " to help. "

 

By adding adjuvants the vaccine can contain less viral antigens, which reduces

production costs.

 

Unfortunately, many of these adjuvants are highly toxic.

 

There are several types of adjuvants. Some of the most commonly used ones

include:

Aluminium hydroxide

Aluminium phosphate

Calcium phosphate

 

Other adjuvants include oil-based emulsions such as squalene, Squalene has not

been licensed by the FDA for use in vaccines distributed in the U.S. yet,

although squalene is an adjuvant used in vaccines distributed in Europe and

other countries.

 

GlaxoKline's proprietary formula ASO3â„¢ and Novartis' MF59â„¢ are two

examples of squalene adjuvants.

 

As damaging as the neurotoxin mercury is, it's important to realize that

aluminum is also a neurotoxin and aluminum-based adjuvants are estimated to be

even MORE toxic than mercury.

 

GREAT NEWS -- No Squalene Allowed in US Swine Flu Vaccines!

Fortunately, Americans can draw a sigh of relief as it pertains to squalene --

one of the most controversial of the adjuvants -- at least for now.

Although vaccine manufacturers were pushing to be allowed to use squalene in

many of the swine flu vaccines, and the US Department of Health and Human

Services purchased spent more than $400 million of tax payers' money to

stockpile the oil-based adjuvant, their efforts have been unsuccessful so far..

In order to legally allow unlicensed squalene adjuvants to be included in

licensed H1N1 vaccines, the US government would have had to issue an Emergency

Use Authorization (EUA).

There have been small H1N1clinical trials in which experimental squalene

adjuvants were included and tested, which have been reported by various media

sources, fueling the questions about its use. But that is different from an FDA

licensed vaccine that is made available for general public use.

To date, no EUA has been issued, so the swine flu vaccines licensed for use in

the US do NOT contain squalene. However, it is still unclear whether the

National Emergency declaration issued by President Obama on October 23, 2009,

will cover adding novel adjuvants like squalene, or whether a separate EUA must

be issued to allow the use of unlicensed adjuvants.

The best way to confirm the existence of vaccine components is to consult the

vaccine product manufacturer inserts. Below, you will find links to the inserts

for the four H1N1 vaccines licensed for use in the US.

You may also want to review the transcript of the July 23, 2009 meeting of the

FDA Vaccines & Related Biological Products Advisory Committee for more

information on the discussion about whether the FDA should issue an EUA and

allow unlicensed adjuvants in US vaccines.

Thankfully, so far, the FDA has declined to approve squalene adjuvants for US

H1N1 vaccines, but that does not mean that the drug companies will not continue

to press for approval in the future.

Beware: European Vaccines May Contain Squalene

Unfortunately, vaccine manufacturers have persuaded countries in Europe and

elsewhere to add squalene to seasonal influenza and H1N1 vaccines, so if you

live outside the US, you will need to do some further research to determine

which vaccines may contain squalene.

A recent article in the English version of the German news source The Local, for

example, warns that the German Defense Ministry has ordered a special stock of

H1N1 vaccines for their troops that will contain neither mercury nor adjuvants,

whereas the general public will be given vaccines containing both.

When checking for squalene, beware that the ingredient called MF59â„¢ is an

oil-in-water emulsion of squalene, Tweenâ„¢80 (polyoxyethylene sorbitan

monooleate), and sorbitan trioleate.

MF59 is approved for human use in Europe, but not in the U.S.

Four Swine Flu Vaccines have Gained US FDA Approval

Below I will review the list of ingredients for the four swine flu vaccines that

gained U.S. FDA approval on September 15. (As of this writing, GlaxoKline

is the only contracted vaccine manufacturer that has not yet gotten their swine

flu vaccine approved.)

Please note that there may be additional anti-virals available that are being

used to treat swine flu, and/or swine flu vaccines on the market in other

countries, but this article only covers the following four vaccines that have

received FDA approval for use in the US:

MedImmune (intranasal spray)

Novartis

Sanofi-Pasteur

CSL

These companies, along with GlaxoKline, have all been awarded contracts by

the U.S. Department of Health and Human Services (HHS) for development and

production of more than 195 million doses of swine flu vaccine.

For more information, warnings and side effects of each ingredient, please

follow the hyperlinks provided.

MedImmune

MedImmune, which is a subsidiary of London-based AstraZeneca, offers an

intranasal spray that contains live attenuated virus. The package insert for

MedImmune's intranasal vaccine can be found here.

Please note that the adverse reaction information for MedImmune's vaccine is

based on studies conducted with the seasonal flu version known as FluMist..

Please review the insert for numerous warnings, contraindications, and adverse

reactions.

Of special note are the warnings that it should not be administrated to children

and adolescents (2-17 years of age) receiving aspirin therapy or

aspirin-containing therapy, because of association of Reye's syndrome.

In addition, it's important to realize that safety has not been established in

individuals with underlying medical conditions predisposing them to influenza

complications.

MedImmune's vaccine also should not be administered to any individual with

asthma, or children under the age of 5 with recurring wheezing because of the

potential for increased risk of wheezing post vaccination.

Lastly, please note that some viruses contained in this and other intranasal

vaccines CAN spread from the vaccinated person to others. Hence, if a person has

a compromised immune system, he or she could be placed at risk of infection from

people who have been vaccinated. The ease of transmission appears to vary from

strain to strain.

Dosing Instructions for MedImmune Intranasal Spray vaccine:

Children 0-2 years: Not approved

Children 2-9 years: 2 doses, 0.2 ml each, approximately one month apart

Children and adults between the ages of 10-49 years: 1 dose, 0.2 ml

Adults 50-65: Not approved, as FluMist was found to have no demonstrable

effectiveness in this age group

Seniors 65 and over: Not approved

Pregnant women: Not recommended

Ingredients include:

Live, attenuated virus

Monosodium glutamate. MSG is a known neurotoxin and excitotoxin.

Egg proteins

Sucrose (table sugar)

Dibasic potassium phosphate

Monobasic potassium phosphate

Gentamicin sulfate (antibiotic)

Intranasal vaccines do not contain thimerosal (mercury).

Questionable Efficacy…

According to the insert, FluMist has demonstrated a mere 44.5 percent reduction

in influenza rate when looking at all strains, compared to active controls

(other flu vaccines).

Novartis

The package insert for Novartis' Influenza A(H1N1) 2009 Monovalent vaccine can

be found here.

Again, the adverse reaction information for this swine flu vaccine is based on

studies conducted with the seasonal flu vaccine Fluvirin, not the A(H1N1)

vaccine itself.

It is worth noting that the safety data for Fluvarin (upon which the safety data

for the swine flu vaccine is based), was collected from 29 clinical studies over

the past 27 years that included no more than 2,768 adults.

In these studies, the subjects were observed for 30 minutes after vaccination,

and were instructed to complete a diary card for the three days following

immunization, to collect local and systemic reactions.

So, keep in mind that the " safety data " for this vaccine is based on studying

human subjects for FOUR DAYS. Not weeks, months, or years, to see if problems

occur down the line.

Please review the insert for numerous warnings, contraindications, and adverse

reactions.

Dosing Instructions (intra-muscular injection):

Children 0-4: Not recommended

Children 4-9: Two 0.5 ml doses one month apart

Children 9-17: One 0.5 ml dose

Adults, 18 and over: One 0.5 ml dose

Ingredients include:

Inactivated A/California/7/2009(H1N1)v-like virus derived from cell-cultures

using dog kidneys. Physorg.com http://www.physorg.com/news175767804.html

recently reported that a Swiss authority overseeing medicine and therapeutical

products had found bacterial contamination in test batches of the vaccine -- a

charge that Novartis has denied.

Single-dose vials contain 1 mcg of mercury per 0.5 ml dose

Multi-dose vials contain 25 mcg of mercury per 0.5 ml dose

Egg proteins

Polymyxin (antibiotic)

Neomycin (antibiotic found in many topical medications). Neomycin is in the FDA

pregnancy category D. This means that it is known to be harmful to fetuses.

Beta-propiolactone (a disinfectant). According to the EPA: " No information is

available on the chronic (long-term), reproductive, developmental, or

carcinogenic effects of beta-propiolactone in humans. The International Agency

for Research on Cancer (IARC) has classified beta-propiolactone as a Group 2B,

possible human carcinogen. "

Nonylphenol ethoxylate (NPE) (a toxic cleaning agent)

Sanofi-Pasteur

The package insert for Sanofi-Pasteur's Influenza A(H1N1) 2009 Monovalent

vaccine can be found here.

The adverse reaction information for Sanofi-Pasteur's vaccine is based on

studies conducted with the seasonal flu version known as Fluzone. The safety

data for infants under the age of 3 is based on adverse reactions of 19

children, reported within a mere three days of vaccination.

Please review the insert for numerous warnings, contraindications, and adverse

reactions.

Dosing Instructions (intra-muscular injection):

Children 0-5 months: Not approved

Children 6-35 months: two 0.25 ml doses, approximately one month apart

Children 36 months to 9 years: two 0.5 ml doses, approximately one month apart

Children 10 years and older: one 0.5 ml dose

Adults: one 0.5 ml dose

Ingredients include:

Inactivated A/California/7/2009(H1N1)v-like virus propagated in embryonated

chicken eggs

Prefilled pediatric syringes and single-dose vials are mercury-free

Multi-dose vials contain 25 mcg of mercury per 0.5 ml dose

Formaldehyde (up to 100 mcg). Formaldehyde is classifed as a probable human

carcinogen by the U.S. Environmental Protection Agency, and as a known human

carcinogen by the International Agency for Research on Cancer.

Triton-X 100 (Polyethylene glycol P-isooctylphenyl ether) is a toxic detergent

Sodium phosphate

Sodium chloride (table salt)

Gelatin

Sucrose (table sugar)

CSL Biotherapies, Inc.

The package insert for CSL's Influenza A(H1N1) 2009 Monovalent vaccine can be

found here.

The adverse reaction information for CSL's vaccine is based on studies conducted

with the seasonal flu version known as Afluria.

Here the safety data is based on adverse reactions reported within 21 days of

vaccination. It's also worth noting that the safety assessment studies were done

using mercury-containing placebos, which may significantly skew the data as the

control group would most likely experience similar side effects of the

thimerosal as those receiving the actual vaccine.

Additionally, tucked away on page 10 it states that:

" No controlled clinical studies demonstrating a decrease in influenza disease

after vaccination with Afluria have been performed. "

Please review the insert for numerous warnings, contraindications, and adverse

reactions.

Dosing Instructions (intra-muscular injection):

Adults only, 18 years and older: one 0.5 ml dose

Ingredients include:

Inactivated A/California/7/2009(H1N1)v-like virus propagated in embryonated

chicken eggs

Single-dose vials are mercury-free

Multi-dose vials contain 24.5 mcg of mercury per 0.5 ml dose

Polymyxin (antibiotic)

Neomycin (antibiotic found in many topical medications). Neomycin is in the FDA

pregnancy category D. This means that it is known to be harmful to fetuses.

Sodium chloride (table salt)

Monobasic sodium phosphate

Dibasic sodium phosphate

Monobasic potassium phosphate

Potassium chloride

Calcium chloride

Sodium taurodeoxycholate (detergent)

Egg proteins (ovalbumin)

Beta-propiolactone (a disinfectant). According to the EPA: " No information is

available on the chronic (long-term), reproductive, developmental, or

carcinogenic effects of beta-propiolactone in humans. The International Agency

for Research on Cancer (IARC) has classified beta-propiolactone as a Group 2B,

possible human carcinogen. "

How Effective is the H1N1 Vaccine, Really?

" Specific levels of HI antibody titers post-vaccination with inactivated

influenza virus vaccine have not been correlated with protection from influenza

virus. In some human studies, antibody titers of 1:40 or greater have been

associated with protection from influenza illness in up to 50% of subjects. "

You will find that paragraph in all the vaccine inserts.

 

What that paragraph says, is that the vaccine only works in half, or less, of

those individuals who attain the specified level of seroconversion after

vaccination. The FDA defines seroconversion as achieving an antibody titer of

1:40.

 

This means that if a vaccine was 100 percent effective at achieving this level

of seroconversion, it would protect up to 50 percent of the recipients of the

vaccine.

But none of the vaccines are 100 percent effective at achieving seroconversion.

 

CSL's vaccine insert, for example, (see pages 11-12), states that their H1N1

vaccine provides seroconversion for:

48.7 percent of people aged 18-65

34 percent for seniors, 65 and older

 

That means that, at best, their vaccine works in one out of every four people!

(49 percent of 50 percent).

 

Which, of course, means that the vaccine does NOT work in three out of every

four people…

 

Is it REALLY worth it?

Final Thoughts

Hopefully, this compilation of data will help you weigh the risks and benefits,

to make a more educated decision for yourself and your family.

 

You can also print out these fact-filled posters that we created. Feel free to

share them any way you like around your community, at local stores, offices, and

schools.

 

Lastly, please remember to bookmark the special section of my site devoted to

all the latest H1N1 Swine Flu Alerts. It's an excellent go-to source to stay

updated on all the new swine flu developments.